Dantron

Dantron (INN), also known as chrysazin or 1,8-dihydroxyanthraquinone, is an organic substance, formally derived from anthraquinone by the replacement of two hydrogen atoms by hydroxyl groups (–OH). It is used in some countries as a stimulant laxative.

Dantron
Clinical data
Routes of
administration		Oral, rectal (enema)
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
NIAID ChemDB
CompTox Dashboard (EPA)
ECHA InfoCard100.003.794
Chemical and physical data
FormulaC14H8O4
Molar mass240.214 g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

It should not be confused with ondansetron, an unrelated drug that was marketed in South Africa under the trade name "Dantron".

Medical uses

In the USA, dantron is not used because it is considered to be a carcinogen.[1]

In the UK it is considered a possible carcinogen and so its use is restricted to patients who already have a diagnosis of terminal cancer. It is mainly used in palliative care to counteract the constipating effects of opioids. Its British Approved Name was danthron, but it has now been changed to "dantron", the recommended International Nonproprietary Name.[2]

Dantron can be administered orally, or can be administered rectally as an enema either in combination with other laxatives or alone.[3]

Side effects

Dantron has the notable side-effect of causing red-colored urine.

See also

References
  1. Danthron substance profile at the National Toxicology Program website
  2. British National Formulary website (requires free registration)
  3. "A06AG Enemas". WHO Collaborating Centre for Drug Statistics Methodology. World Health Organization. 13 December 2018. Retrieved 17 March 2019.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.